Navigation Links
'Self-seeding' of cancer cells may play a critical role in tumor progression
Date:12/24/2009

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan-Kettering Cancer Center shows that circulating tumor cells cancer cells that break away from a primary tumor and disseminate to other areas of the body can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."

The findings of the study, published in the December 25 issue of the journal Cell, suggest that self-seeding can enhance tumor growth through the release of signals that promote angiogenesis, invasion, and metastasis.

"Our work not only provides evidence for the self-seeding phenomenon and reveals the mechanism of this process, but it also shows the possible role of self-seeding in tumor progression," said the study's first author Mi-Young Kim, PhD, Research Fellow in the Cancer Biology and Genetics Program at Memorial Sloan-Kettering.

According to the research, which was conducted in mice, self-seeding involves two distinct functions: the ability of a tumor to attract its own circulating progeny and the ability of circulating tumor cells to re-infiltrate the tumor in response to this attraction. The investigators identified four genes that are responsible for executing these functions: IL-6 and IL-8, which attract the most aggressive segment of the circulating tumor cells population, and FSCN1 and MMP1, which mediate the infiltration of circulating tumor cells into a tumor.

The findings also show that circulating breast cancer cells that are capable of self-seeding a breast tumor have a similar gene expression pattern to breast cancer cells that are capable of spreading to the lungs, bones, and brain, and therefore have an increased potential to metastasize to these organs. Additional experiments revealed that self-seeding can occur in cancer cells of various tumor types in addition to breast cancer, including colon cancer and melanoma.

"These results provide us with opportunities to explore new targeted therapies that may interfere with the self-seeding process and perhaps slow or even prevent tumor progression," said the study's senior author, Joan Massagu, PhD, Chair of the Cancer Biology and Genetics Program at Memorial Sloan-Kettering and a Howard Hughes Medical Institute investigator.

The concept of self-seeding sheds light on clinical observations such as the relationship between the tumor size, prognosis, and local relapse following seemingly complete removal of a primary breast tumor. "We know there is an association between large tumor size and poor prognosis. This was always thought to reflect the ability of larger cancers to release more cells with metastatic potential. But this association may actually be caused by the ability of aggressive cancer cells to self-seed, promoting both local tumor growth and distant metastases by similar mechanisms," said study co-author Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
646-227-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Research Reveals How Breast Cancer Rearranges Genome
2. Alzheimers May Stave Off Cancer, and Vice Versa
3. Broken genomes behind breast cancers
4. Two Genes Work in Tandem to Spur Deadliest Brain Cancer
5. Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target
6. New insights into mushroom-derived drug promising for cancer treatment
7. Ingredient in Botanicals Tied to Urinary Cancer
8. New iPhone App Provides New Services for Cancer Patients
9. Chicago Cancer Genome Project studies genetics of 1,000 tumors
10. UAB will carry out an in-depth study of the effects olive oil has on the prevention of breast cancer
11. Lung Cancer Foundation of America Gives the Gift of Life This Holiday Season: Announces Inaugural $125,000 Scientific Research Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: